Brief: Egetis: FDA Awards Tiratricol Breakthrough Therapy Designation In July 2025
18/08/2025 09:49
Aug 18 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST: FDA AWARDS TIRATRICOL BREAKTHROUGH THERAPY DESIGNATION IN JULY 2025 SUBMITS PRE-NDA MEETING REQUEST TO FDA FOR TIRATRICOL PLANS NDA SUBMISSION FOR TIRATRICOL IN 2025 15 EVALUABLE PATIENTS IN RETRIACT STUDY Source text: ID:nMFN1PzrQC Further company coverage: EGTX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))